Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)

Kaplan, Mehmet Ali; Işıkdoğan, Abdurrahman; Koca, Doğan; Küçüköner, Mehmet; Gümüşay, Özge; Yıldız, Ramazan; Dayan, Adem; Demir, Lutfiye; Geredeli, Caglayan; Koçer, Murat; Arslan, Ulku Yalcintas; İnal, Ali; Ünal, Olçun Ümit; Mert, Aslıhan Güven; Bilici, Mehmet; Özkan, Metin; Elkıran, Emin Tamer; Yaman, Samet; Durnalı, Ayşe; Suner, Ali; Alıcı, Süleyman; Tarhan, Mustafa Oktay; Boruban, Cem; Urakçı, Zuhat; Büyükberber, Süleyman

doi:10.1159/000338782

Cited by 24 publications

(21 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Niwinska et al reported improvements in median survival from 3 to 14 months with the addition of systemic therapy in patients with luminal breast cancer [ 20 ]. A similar result was seen in another study where the median overall survival of patients with luminal breast cancer was improved from 7.1 to 14.3 months with chemotherapy [ 55 ].…”

Section: Systemic Therapiessupporting

confidence: 86%

Breast cancer brain metastases: the last frontier

Leone

Leone²

2015

Exp Hematol Oncol

138

111

View full text Add to dashboard Cite

Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10–16 % of patients. Longer survival of patients with metastatic breast cancer and the use of better imaging techniques are associated with an increased incidence of brain metastases. Unfortunately, patients who develop brain metastases tend to have poor prognosis with short overall survival. In addition, brain metastases are a major cause of morbidity, associated with progressive neurologic deficits that result in a reduced quality of life. Tumor subtypes play a key role in prognosis and treatment selection. Current therapies include surgery, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy and targeted therapies. However, the timing and appropriate use of these therapies is controversial and careful patient selection by using available prognostic tools is extremely important. This review will focus on current treatment options, novel therapies, future approaches and ongoing clinical trials for patients with breast cancer brain metastases.

show abstract

Section: Systemic Therapiessupporting

confidence: 86%

Breast cancer brain metastases: the last frontier

Leone

Leone²

2015

Exp Hematol Oncol

138

111

View full text Add to dashboard Cite

show abstract

“…In a retrospective study of over 135 patients with BM from LBC, 88.8 % of them received local therapy (WBRT, RS or SRT), 56.7 % chemotherapy (mostly with taxanes) and 30.6 % hormonal therapy (mostly with aromatase inhibitors). Systemic treatment (chemotherapy ± hormonal therapy ± target therapy) prolonged median OS (14.3 vs 7.1 months, p = 0.03) [52]. These data have been recently confirmed in a prospective study including 420 patients: OS with systemic treatment after WBRT increased 9 months in LBC [33].…”

Section: Systemic Anticancer Treatment By Tumor Subtypesmentioning

confidence: 86%

Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline

et al. 2013

View full text Add to dashboard Cite

Breast cancer represents the second most frequent etiology of brain metastasis (BM). It is estimated that 10–30 % of patients with breast cancer are diagnosed with BM. Breast cancer BM are increasing due to the aging population, detection of subclinical disease, and better control of systemic disease. BM is a major cause of morbidity and mortality affecting neurocognition, speech, coordination, behavior, and quality of life. The therapy of BM remains controversial regarding use and timing of surgical resection, application of whole-brain radiotherapy, stereotactic radiosurgery and systemic drugs in patients with particular tumor subtypes. Despite numerous trials, the range of interpretation of these has resulted in differing treatment perspectives. This paper is a review of the state of the art and a multidisciplinary guideline on strategies to improve the therapeutic index in this situation.

show abstract

“…Human epidermal growth factor receptor (HER)2-positive and triple-negative breast cancer (TNBC) patients also have a higher risk of BM compared with luminal cancer patients [ 4 , 5 ]. In HER2-positive and TNBC patients, incidences of BM as high as 30–40 % have been described (Table 1 ) [ 4 – 6 ].…”

Section: Epidemiology Incidence and Risk Factorsmentioning

confidence: 99%

Breast cancer brain metastases: biology and new clinical perspectives

et al. 2016

View full text Add to dashboard Cite

Because of improvements in the treatment of patients with metastatic breast cancer, the development of brain metastases (BM) has become a major limitation of life expectancy and quality of life for many breast cancer patients. The improvement of management strategies for BM is thus an important clinical challenge, especially among high-risk patients such as human epidermal growth factor receptor 2-positive and triple-negative patients. However, the formation of BM as a multistep process is thus far poorly understood. To grow in the brain, single tumor cells must pass through the tight blood–brain barrier (BBB). The BBB represents an obstacle for circulating tumor cells entering the brain, but it also plays a protective role against immune cell and toxic agents once metastatic cells have colonized the cerebral compartment. Furthermore, animal studies have shown that, after passing the BBB, the tumor cells not only require close contact with endothelial cells but also interact closely with many different brain residential cells. Thus, in addition to a genetic predisposition of the tumor cells, cellular adaptation processes within the new microenvironment may also determine the ability of a tumor cell to metastasize. In this review, we summarize the biology of breast cancer that has spread into the brain and discuss the implications for current and potential future treatment strategies.

show abstract

Biological Subtypes and Survival Outcomes in Breast Cancer Patients with Brain Metastases (Study of the Anatolian Society of Medical Oncology)

Cited by 24 publications

References 66 publications

Breast cancer brain metastases: the last frontier

Breast cancer brain metastases: the last frontier

Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline

Breast cancer brain metastases: biology and new clinical perspectives

Contact Info

Product

Resources

About